Pieris Pharmaceuticals Inc (FRA:PI60)
€ 10.064 0 (0%) Market Cap: 17.14 Mil Enterprise Value: -8.03 Mil PE Ratio: 0 PB Ratio: 1.10 GF Score: 44/100

Pieris Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference Sponsored by H C Wainwright (Virtual) Transcript

Sep 16, 2020 / 06:00PM GMT
Release Date Price: €194.16 (+0.71%)
Emanuela Branchetti
H.C. Wainwright & Co., LLC

And we are moving on to our next presentation. Our next presenter is Stephen Yoder, who is the Chief Executive Officer, of Pieris. Pieris is focused on the development of Anticalin protein-based drugs, targeting cancer and respiratory diseases.

So please join me in welcoming Stephen Yoder.

Stephen S. Yoder
Pieris Pharmaceuticals, Inc. - CEO, President & Director

Well, thank you, Emanuela. Thank you to H.C. Wainwright for the invitation to present today. And I'm happy to spend the next 15 minutes or so providing a corporate update on Pieris Pharmaceuticals.

For those of you who don't know us, we are a next-generation therapeutic protein company that has, as Emanuela mentioned, a proprietary class of molecules that we call Anticalins. And today, I want to focus our discussion on the clinical data we've generated with the 2 programs, PRS-060 and PRS-343. And then, more importantly, I want to discuss the planned upcoming clinical proof-of-concept trials for each of those programs. As I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot